Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells

Introduction of the proteasome inhibitor bortezomib has dramatically improved clinical outcomes in multiple myeloma. However, most patients become refractory to bortezomib-based therapies. On the molecular level, development of resistance to bortezomib in myeloma cells is accompanied by complex meta...

Descripción completa

Detalles Bibliográficos
Autores principales: Byrgazov, Konstantin, Besse, Andrej, Kraus, Marianne, Slipicevic, Ana, Lehmann, Fredrik, Driessen, Christoph, Besse, Lenka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202573/
https://www.ncbi.nlm.nih.gov/pubmed/34136753
http://dx.doi.org/10.1097/HS9.0000000000000602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202573/
https://www.ncbi.nlm.nih.gov/pubmed/34136753
http://dx.doi.org/10.1097/HS9.0000000000000602

Ejemplares similares